Prevention, technology-enabled whole-person care, real-time measurement, simplification, and accelerated innovation were key themes at the recent quality conference.
On March 17-18, the ICD-10 C&M Committee discussed proposals for 35+ new codes designed to improve accuracy, address emerging health issues, and strengthen disease reporting.
Changes in state and federal policies will drive patient access, financing, and provider reimbursement of cell and gene therapies.
Avalere Health Advisory experts unpack the recent state legislative activity around AI in healthcare, exploring recent trends, the impact of federal executive orders, and key considerations for industry stakeholders as they navigate these shifts.
European countries are advancing real-world data use in healthcare decision-making, but face challenges from differing national frameworks and regulations
Evolving digital health codes are reshaping how technology and care connect.
Distinct patient characteristics and cost profiles across rare epilepsies reinforce the value of disease-specific approaches in rare disease research.
Avalere Health experts discuss how they developed and deployed an analytic model to predict likely enrollment changes to assist clients in understanding the impacts on all lines of business as a result of upcoming federal policy changes.
CMS’s post-IRA updates to the RxHCC risk adjustment model have varying effects on plan loss ratios across therapeutic areas.
With IRA, MFN, and OBBBA pressures, manufacturers must assess coverage shifts, demographics, and payer mix to refine channel strategy and improve patient access.
Facing financial pressures, independent pharmacies adapt to remain viable, offering home delivery, vaccinations, compounding, and medication synchronization.
State oversight of AI in healthcare has primarily focused on prior authorization, disclosure and operations requirements, and scope of practice.
Avalere Health Advisory experts discuss how compendium shape off-label drug use, underscoring both benefits and risks in clinical decision-making.
The European Health Data Space aims to enable secure, unified health data access across Europe, supporting research, innovation, and improved patient outcomes.
In the second installment of our Inside Compendia series, Avalere Health Advisory experts discuss how compendia can support clinical decision-making and medication access, highlighting a case study on GLP-1s.
For IPAY 2028 and beyond, the OBBBA expands the exclusion for orphan drugs subject to Medicare negotiation, with implications for negotiation selection timing.
The 2025 edition of the annual report provides insights into state statutes on point-of-service substitution of biosimilar products and is available
The unwinding of COVID-era Medicaid continuous enrollment policies resulted in insurance coverage losses and challenged vaccine access for adults.
In the first installment of our Inside Compendia series, Avalere Health Advisory experts discuss how to engage and support life sciences companies in ways of incorporating their products into clinical compendia and guidelines.
In Kennedy v. Braidwood, the Supreme Court affirmed HHS’s USPSTF appointment power, keeping the ACA’s no-cost preventive-service mandate fully in force.
